Doxorubicin alone versus intensified doxorubicin plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: A randomised controlled phase 3 trial

The Lancet Oncology

Volumn 15, Issue 4, 2014, Pages 415-423

  Judson, Ian ^a   Verweij, Jaap ^b   Gelderblom, Hans ^c   Hartmann, Jörg T ^d,e,f   Schöffski, Patrick ^g   Blay, Jean Yves ^h   Kerst, J Martijn ⁱ   Sufliarsky, Josef ^j   Whelan, Jeremy ^k   Hohenberger, Peter ^l   Krarup Hansen, Anders ^m   Alcindor, Thierry ^n,o   Marreaud, Sandrine ^p   Litière, Saskia ^p   Hermans, Catherine ^p   Fisher, Cyril ^a   Hogendoorn, Pancras C W ^c   Dei Tos, A Paolo ^q   Van der Graaf, Winette T A ^r  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b ERASMUS MC CANCER INSTITUTE   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e UNIVERSITY OF KIEL   (Germany)

^f Catholic Hospital   (Germany)

^g UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^h CENTRE LÉON BÉRARD   (France)

ⁱ NETHERLANDS CANCER INSTITUTE   (Netherlands)

^j CANCER RESEARCH INSTITUTE   (Slovakia)

^k UNIVERSITY COLLEGE HOSPITAL   (United Kingdom)

^l UNIVERSITY OF HEIDELBERG   (Germany)

^m UNIVERSITY OF COPENHAGEN   (Denmark)

ⁿ MCGILL UNIVERSITY   (Canada)

^o MONTREAL GENERAL HOSPITAL   (Canada)

^p EORTC DATA CENTER   (Belgium)

^q Azienda ULSS 9   (Italy)

^r RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

more..

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; IFOSFAMIDE;

ADULT; ANEMIA; ARTICLE; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER SURVIVAL; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HUMAN; KIDNEY DISEASE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MONOTHERAPY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SOFT TISSUE SARCOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; EUROPE; FEMALE; HUMANS; IFOSFAMIDE; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PALLIATIVE CARE; PATIENT SELECTION; RISK FACTORS; SARCOMA; SOFT TISSUE NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; TUMOR BURDEN; YOUNG ADULT;

EID: 84897031194     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(14)70063-4     Document Type: Article

References (32)

1. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial. Lancet 2004, 364:1127-1134.
2. Blay JY, El Sayadi H, Thiesse P, Garret J, Ray-Coquard I Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). Ann Oncol 2008, 19:821-822.
3. Rutkowski P, Van Glabbeke M, Rankin CJ, et al. Imatinib mesylate in advanced dermatofibrosarcoma protuberans: pooled analysis of two phase II clinical trials. J Clin Oncol 2010, 28:1772-1791. the European Organisation for Research and Treatment of Cancer Soft Tissue, Bone Sarcoma GroupBone Sarcoma Group, the Southwest Oncology Groupthe Southwest Oncology Group.
4. Wagner AJ, Malinowska-Kolodziej I, Morgan JA, et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1 in tumors. J Clin Oncol 2010, 28:835-840.
5. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer 2008, 112:1585-1591.
6. Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX Study. J Clin Oncol 2008, 26:5269-5274.
7. Skubitz KM, Haddad PA Paclitaxel and pegylated-liposomal doxorubicin are both active in angiosarcoma. Cancer 2005, 104:361-366.
8. Hensley ML, Blessing JA, Mannel R, Rose PG Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol 2008, 109:329-334.
9. Maki RG, Wathen JK, Patel SR, et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002. J Clin Oncol 2007, 25:2755-2763.
10. van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma patients. Eur J Cancer 2002, 38:2397-2406. the EORTC Soft Tissue and Bone Sarcoma Group.
11. Patel SR, Vadhan-Raj S, Burgess MA, et al. Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 1998, 21:317-321.
12. Reichardt P, Tilgner J, Hohenberger P, Dörken B Dose-intensive chemotherapy with ifosfamide, epirubicin, and filgrastim for adult patients with metastatic or locally advanced soft tissue sarcoma: a phase II study. J Clin Oncol 1998, 16:1438-1443.
13. Leyvraz S, Zweifel M, Jundt G, et al. Long-term results of a multicenter SAKK trial on high-dose ifosfamide and doxorubicin in advanced or metastatic gynecologic sarcomas. Ann Oncol 2006, 17:646-651. the Swiss Group for Clinical Cancer Research.
14. Van Glabbeke M, Verweij J, Judson I, Nielsen OS Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer 2002, 38:543-549. the EORTC Soft Tissue and Bone Sarcoma Group.
15. Guillou L, Coindre JM, Bonichon F, et al. Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. J Clin Oncol 1997, 15:350-362.
16. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000, 92:205-216.
17. Handbook for reporting results for cancer treatment 1979, WHO, World Health Organization, Geneva.
18. Common Toxicity Criteria, version 2.0 1998, Cancer Therapy Evaluation Program, DCTD, NCI, NIH, DHHS.
19. Van Glabbeke M, Van Oosterom AT, Oosterhuis JW, et al. Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthracycline-containing first-line regimens-A European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. J Clin Oncol 2002, 7:821-828.
20. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 1995, 13:1537-1545.
21. Edmonson JH, Ryan LM, Blum RH, et al. Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 1993, 11:1269-1275.
22. Antman K, Crowley J, Balcerzak SP, et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol 1993, 11:1276-1285.
23. 2 of ifosfamide plus doxorubicin and G-CSF in the treatment of poor-prognosis soft tissue sarcoma. J Clin Oncol 2005, 23:105-112.
24. Fayette J, Penel N, Chevreau C, et al. Phase III trial of standard versus dose-intensified doxorubicin, ifosfamide and dacarbazine (MAID) in the first-line treatment of metastatic and locally advanced soft tissue sarcoma. Invest New Drugs 2009, 27:482-489.
25. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: A trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol 2000, 18:2676-2684.
26. Maurel J, López-Pousa A, de Las Peñas R, et al. Efficacy of sequential high-dose doxorubicin and ifosfamide compared with standard-dose doxorubicin in patients with advanced soft tissue sarcoma: an open-label randomized phase II study of the Spanish group for research on sarcomas. J Clin Oncol 2009, 27:1893-1898.
27. Bui-Nguyen B, Ray-Coquard I, Chevreau C, et al. High-dose chemotherapy consolidation for chemosensitive advanced soft tissue sarcoma patients: an open-label, randomized controlled trial. Ann Oncol 2012, 23:777-784. the GSF-GETO French Sarcoma Group.
28. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M Dose-intensive chemotherapy with growth factor or autologous bone marrow/stem cell transplant support in first-line treatment of advanced or metastatic adult soft tissue sarcoma: a systematic review. Cancer 2008, 112:1197-1205. the Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-based Care.
29. Verma S, Younus J, Stys-Norman D, Haynes AE, Blackstein M Meta-analysis of ifosfamide-based combination chemotherapy in advanced soft tissue sarcoma. Cancer Treat Rev 2008, 34:339-347. the Members of the Sarcoma Disease Site Group of Cancer Care Ontario's Program in Evidence-Based Care.
30. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer 2010, 46:72-83.
31. Ryan CW, Schoffski P, Merimsky O, et al. PICASSO 3: a phase 3 international randomized double blind placebo-controlled study of doxorubicin plus palifosfamide vs. doxorubicin plus placebo for patients in first-line for metastatic soft tissue sarcoma. Eur J Cancer 2013, 49(suppl 2). abstr 3802,S876.
32. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 2012, 379:1879-1886.